BIOS
  • About
  • Investor Relations
    • SEC Filings
    • IPO Prospectus
    • Corporate Governance
    • Tax
  • Value Add
  • Acquisition Criteria
  • Leadership
  • News
  • Contact
Select Page

Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation

by Dakota | May 3, 2023 | Uncategorized

View Press Release On GlobeNewswire – Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent...

8-K Filing Pursuant to Full Exercise of Over-Allotment Option

by Dakota | Dec 8, 2021 | Uncategorized

 BioPlus Acquisition Corp. Announces Full Over-Allotment Exercise FORM...

Recent Posts

  • Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation
  • 8-K Filing Pursuant to Full Exercise of Over-Allotment Option
  • BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offering

Recent Comments

    BIOS Acquisition Corp.

    260 Madison Ave, 8th Floor
    New York, NY 10016
    NASDAQ: BIOS
    info@biosspac.com

    Quick Links

    About

    Leadership

    Press Releases

    Contact

    BIOS Acquisition Corporation © 2022 All Rights Reserved
    One Up